Fate Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Fate Therapeutics, Inc. (FATE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-186.26-160.93-281.72-212.15-173.39-98.15-66.60
Depreciation & Amortization18.9618.2813.7610.974.781.841.20
Stock Based Compensation41.5043.4678.7354.3630.750.000.00
Change in Working Capital-1.9619.18-34.71-18.8639.95-5.661.74
Change in Accounts Receivable-1.1136.65-29.80-3.16-5.520.000.00
Change in Accounts Payable-1.66-28.9414.255.91-1.550.000.00
Change in Other Working Capital-1.7111.47-24.01-0.65-5.700.000.00
Other Operating Activities-1.71-48.06-24.0157.23-5.9618.8019.04
Net Cash from Operating Activities-122.87-132.26-248.21-162.87-39.23-83.18-38.65
Investing Activities
Capital Expenditures-0.73-6.15-35.5750.704.937.40-2.30
Purchases of Investments-317.75118.82-404.80-273.32-156.140.000.00
Sales/Maturities of Investments330.70-358.81607.11-273.32-156.14-150.061.84
Net Cash from Investing Activities12.22112.67166.75-324.02-161.08-157.45-0.46
Financing Activities
Debt Repayment0.000.000.000.000.00-15.000.00
Common Stock Issued74.530.099.21411.74238.76162.41134.58
Other Financing Activities5.070.000.00411.7434.420.003.51
Net Cash from Financing Activities99.890.099.21453.13282.84149.93140.78
Summary
Effect of Forex Changes on Cash4.950.000.000.000.000.000.00
Net Change in Cash-10.76-19.51-72.25-33.7682.53-90.70101.67
Cash at Beginning of Period57.0576.56148.81182.57100.04190.7489.07
Cash at End of Period46.28-497.2176.56148.81100.04100.04190.74
Free Cash Flow-123.60-138.42-283.77-213.57-44.16-90.57-40.95
Supplemental Disclosures
Interest Paid0.000.000.000.000.002.291.24